Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ETOPOSIDE"" wg kryterium: Temat


Tytuł :
Natural Polyphenols as Modulators of Etoposide Anti-Cancer Activity.
Autorzy :
Kluska M; Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Łódź, Poland.
Woźniak K; Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Łódź, Poland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jun 20; Vol. 22 (12). Date of Electronic Publication: 2021 Jun 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Phytogenic/*pharmacology
Etoposide/*pharmacology
Polyphenols/*pharmacology
Topoisomerase II Inhibitors/*pharmacology
Animals ; Antineoplastic Agents, Phytogenic/chemistry ; Antineoplastic Agents, Phytogenic/therapeutic use ; Biomarkers ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Disease Models, Animal ; Drug Synergism ; Etoposide/therapeutic use ; Humans ; Neoplasms/drug therapy ; Neoplasms/etiology ; Neoplasms/metabolism ; Neoplasms/pathology ; Polyphenols/chemistry ; Polyphenols/therapeutic use ; Structure-Activity Relationship ; Topoisomerase II Inhibitors/therapeutic use ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Association between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients receiving intravenous etoposide.
Autorzy :
Ronsley R; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Jacques L; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Potts JE; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Clement K; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Dix DB; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Mahon P; Division of Hematology, Oncology and Bone Marrow Transplant, British Columbia Children's Hospital, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.; School of Nursing, The University of British Columbia, Vancouver, British Columbia, Canada.
Pokaż więcej
Źródło :
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Apr; Vol. 38 (3), pp. 208-215. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article
MeSH Terms :
Anaphylaxis/*chemically induced
Antineoplastic Agents, Phytogenic/*adverse effects
Etoposide/*adverse effects
Hypersensitivity, Immediate/*chemically induced
Topoisomerase II Inhibitors/*adverse effects
Antineoplastic Agents, Phytogenic/administration & dosage ; Child ; Child, Preschool ; Etoposide/administration & dosage ; Female ; Filtration/instrumentation ; Humans ; Infusions, Intravenous/instrumentation ; Male ; Retrospective Studies ; Topoisomerase II Inhibitors/administration & dosage
Czasopismo naukowe
Tytuł :
DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.
Autorzy :
Maddox JM; Department of Haematology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
Horan M; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Tafesh L; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Shrubsole C; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Osborne W; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Feb; Vol. 192 (3), pp. e92-e94. Date of Electronic Publication: 2020 Dec 18.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chlorambucil/*therapeutic use
Dexamethasone/*therapeutic use
Etoposide/*therapeutic use
Lomustine/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chlorambucil/administration & dosage ; Dexamethasone/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Lomustine/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy
Opinia redakcyjna
Tytuł :
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
Autorzy :
Lee MJ; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Tomita Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Yuno A; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Lee S; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Abrouk NE; Department of Clinical Research, Clinical Trial Innovations , Mountain View, CA, USA.
Oronsky B; Department of Clinical Research, EpicentRx, Inc , La Jolla, CA, USA.
Caroen S; Department of Clinical Research, EpicentRx, Inc , La Jolla, CA, USA.
Trepel JB; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Feb; Vol. 30 (2), pp. 177-183. Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Azetidines/*therapeutic use
Carboplatin/*therapeutic use
Cisplatin/*therapeutic use
Etoposide/*therapeutic use
Lung Neoplasms/*drug therapy
Nitro Compounds/*therapeutic use
Small Cell Lung Carcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azetidines/adverse effects ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Disease Progression ; Etoposide/adverse effects ; HLA-DR Antigens/blood ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Membrane Glycoproteins/blood ; Nitro Compounds/adverse effects ; Receptors, Immunologic/blood ; Small Cell Lung Carcinoma/blood ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/pathology ; Time Factors ; Treatment Outcome ; Tumor-Associated Macrophages/drug effects ; Tumor-Associated Macrophages/metabolism
Czasopismo naukowe
Tytuł :
Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants.
Autorzy :
Wu C; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Yi X; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Xu R; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Zhang M; Laboratory of Pharmaceutical Research, Anhui Zhongren Science and Technology Co., Ltd, Hefei, PR China.
Xu Y; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Ma Y; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Gao L; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Zha Z; School of Food and Biological Engineering, Hefei University of Technology, Hefei, PR China.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2020 Dec; Vol. 27 (1), pp. 974-982.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*pharmacokinetics
Etoposide/*administration & dosage
Etoposide/*pharmacokinetics
Polyesters/*chemistry
Animals ; Antineoplastic Agents/pharmacology ; Calorimetry, Differential Scanning ; Cell Line, Tumor ; Drug Implants ; Drug Liberation ; Etoposide/pharmacology ; Mice ; Rats ; Rats, Wistar ; Spectroscopy, Fourier Transform Infrared ; Technology, Pharmaceutical/methods ; Tissue Distribution
Czasopismo naukowe
Tytuł :
Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells.
Autorzy :
Murphy MB; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University, Park Drive, Nashville, TN 37204, USA.
Kumar P; Department of Biology, Belmont University, 1900 Belmont Boulevard, Nashville, TN 37212, USA.
Bradley AM; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University, Park Drive, Nashville, TN 37204, USA.
Barton CE; Department of Biology, Belmont University, 1900 Belmont Boulevard, Nashville, TN 37212, USA.
Deweese JE; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University, Park Drive, Nashville, TN 37204, USA; Departments of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235, USA.
Mercer SL; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University, Park Drive, Nashville, TN 37204, USA; Departments of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37235, USA. Electronic address: .
Pokaż więcej
Źródło :
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2020 Nov 15; Vol. 28 (22), pp. 115773. Date of Electronic Publication: 2020 Sep 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*pharmacology
DNA Topoisomerases, Type II/*metabolism
Etoposide/*pharmacology
Podophyllotoxin/*pharmacology
Topoisomerase II Inhibitors/*pharmacology
A549 Cells ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; DNA Cleavage ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Etoposide/chemical synthesis ; Etoposide/chemistry ; HCT116 Cells ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Plasmids/drug effects ; Podophyllotoxin/chemical synthesis ; Podophyllotoxin/chemistry ; Structure-Activity Relationship ; Topoisomerase II Inhibitors/chemical synthesis ; Topoisomerase II Inhibitors/chemistry
Czasopismo naukowe
Tytuł :
Impact of RARα and miR-138 on retinoblastoma etoposide resistance.
Autorzy :
Busch M; Institute of Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Miroschnikov N; Institute of Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Dankert JT; Institute of Anatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Wiesehöfer M; Institute of Anatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Metz K; Institute of Pathology, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Stephan H; Division of Haematology and Oncology, Children's Hospital, University of Duisburg-Essen, Essen, Germany.
Dünker N; Institute of Anatomy II, Department of Neuroanatomy, University of Duisburg-Essen, Medical Faculty, Essen, Germany.
Pokaż więcej
Źródło :
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2021; Vol. 43 (1), pp. 11-26.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm/*drug effects
Etoposide/*pharmacology
MicroRNAs/*metabolism
Retinal Neoplasms/*pathology
Retinoblastoma/*pathology
Retinoic Acid Receptor alpha/*metabolism
3' Untranslated Regions ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Cell Survival ; Drug Resistance, Neoplasm/genetics ; Etoposide/therapeutic use ; Gene Expression Regulation, Neoplastic ; Humans ; MicroRNAs/genetics ; Protein Binding ; Retinal Neoplasms/diet therapy ; Retinal Neoplasms/genetics ; Retinoblastoma/drug therapy ; Retinoblastoma/genetics ; Retinoic Acid Receptor alpha/genetics
Czasopismo naukowe
Tytuł :
Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma.
Autorzy :
Perret A; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Dômont J; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Chamseddine AN; Department of International Patients Care, Gustave Roussy Cancer Institute, Villejuif, France.
Dumont SN; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Verret B; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Briand S; Department of Orthopaedic Surgery, Kremlin-Bicêtre Teaching Hospital, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Court C; Department of Orthopaedic Surgery, Kremlin-Bicêtre Teaching Hospital, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Lazure T; Department of Pathology, Kremlin-Bicêtre Teaching Hospital, Université Paris Saclay, Le Kremlin-Bicêtre, France.
Adam J; Department of Pathology, Gustave Roussy Cancer Institute, Villejuif, France.
Ngo C; Department of Pathology, Gustave Roussy Cancer Institute, Villejuif, France.
Even C; Department of Head and Neck Oncology, Gustave Roussy Cancer Institute, Villejuif, France.
Levy A; Department of Radiotherapy, Gustave Roussy Cancer Institute, Villejuif, France.
Bayle A; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Lucibello F; Department of Cancer Medicine, Gustave Roussy Cancer Institute, Villejuif, France.
Haddag-Miliani L; Department of Medical Imaging, Gustave Roussy Cancer Institute, Villejuif, France.
Faron M; Department of Surgery, Gustave Roussy Cancer Institute, Villejuif, France.
Honoré C; Department of Surgery, Gustave Roussy Cancer Institute, Villejuif, France.
Le Cesne A; Department of International Patients Care, Gustave Roussy Cancer Institute, Villejuif, France.
Mir O; Department of Ambulatory Cancer Care, Gustave Roussy Cancer Institute, Villejuif, France.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2021 Jan; Vol. 10 (1), pp. 230-236. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*administration & dosage
Bone Neoplasms/*drug therapy
Etoposide/*administration & dosage
Osteosarcoma/*drug therapy
Administration, Metronomic ; Administration, Oral ; Adult ; Aged ; Antineoplastic Agents, Phytogenic/adverse effects ; Bone Neoplasms/pathology ; Disease Progression ; Etoposide/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Osteosarcoma/secondary ; Progression-Free Survival ; Retrospective Studies ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Six-step etoposide desensitization protocol: A pediatric, adolescent, and young adult case series.
Autorzy :
Stockton W; Department of Pharmacy, Children's Hospital of Orange County, Orange, California.
Lam F; Department of Pharmacy, Children's Hospital of Orange County, Orange, California.
Nguyen T; Department of Pharmacy, Children's Hospital of Orange County, Orange, California.
Nguyen T; Department of Pharmacy, Children's Hospital of Orange County, Orange, California.
Kirov I; Division of Oncology, Hyundai Cancer Institute, Children's Hospital of Orange County, Orange, California.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2021 Jan; Vol. 68 (1), pp. e28795. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*adverse effects
Desensitization, Immunologic/*methods
Drug Hypersensitivity/*prevention & control
Etoposide/*adverse effects
Neoplasms/*drug therapy
Adolescent ; Adult ; Antineoplastic Agents, Phytogenic/immunology ; Child ; Child, Preschool ; Drug Hypersensitivity/etiology ; Etoposide/immunology ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; Neoplasms/immunology ; Neoplasms/pathology ; Prognosis ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Etoposide Loaded SPION-PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis.
Autorzy :
Erkisa M; Bursa Uludag University, Science and Art Faculty, Department of Biology, 16059, Bursa, Turkey.; Istinye University, Faculty of Medicine, Molecular Cancer Research Center, 34010, Istanbul, Turkey.
Ari F; Bursa Uludag University, Science and Art Faculty, Department of Biology, 16059, Bursa, Turkey.
Ulku I; Koc University, Department of Chemistry, 34450, Istanbul, Turkey.
Khodadust R; Koc University, Department of Chemistry, 34450, Istanbul, Turkey.
Yar Y; Koc University, Materials Science and Engineering, 34450, Istanbul, Turkey.
Yagci Acar H; Koc University, Department of Chemistry, 34450, Istanbul, Turkey.; Koc University, Materials Science and Engineering, 34450, Istanbul, Turkey.
Ulukaya E; Istinye University, School of Medicine, Department of Clinical Biochemistry, 34010, Istanbul, Turkey.
Pokaż więcej
Źródło :
Chemistry & biodiversity [Chem Biodivers] 2020 Nov; Vol. 17 (11), pp. e2000607. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Journal Article
MeSH Terms :
Etoposide/*chemistry
Magnetic Iron Oxide Nanoparticles/*chemistry
Acrylic Resins/chemistry ; Apoptosis/drug effects ; Biocompatible Materials/chemistry ; Biocompatible Materials/pharmacology ; Cell Line, Tumor ; Drug Carriers/chemistry ; Etoposide/pharmacology ; Ferric Compounds/chemistry ; Humans ; Magnetic Iron Oxide Nanoparticles/toxicity ; Male ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Autorzy :
Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Dvorkin M; BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia.
Chen Y; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA.
Reinmuth N; Asklepios Lung Clinic, Munich-Gauting, Germany.
Hotta K; Okayama University Hospital, Okayama, Japan.
Trukhin D; Odessa Regional Oncological Dispensary, Odessa, Ukraine.
Statsenko G; Omsk Regional Cancer Centre, Omsk, Russia.
Hochmair MJ; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
Özgüroğlu M; Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey.
Ji JH; Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Garassino MC; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Voitko O; Kyiv City Clinical Oncological Centre, Kiev, Ukraine.
Poltoratskiy A; Petrov Research Institute of Oncology, St Petersburg, Russia.
Ponce S; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
Verderame F; Azienda Ospedaliera Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy.
Havel L; Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Bondarenko I; Dnipropetrovsk Medical Academy, Dnipro, Ukraine.
Każarnowicz A; Tuberculosis and Lung Disease Hospital, Olsztyn, Poland.
Losonczy G; Department of Pulmonology, Semmelweis University, Budapest, Hungary.
Conev NV; Clinic of Medical Oncology, University Multiprofile Hospital for Active Treatment St Marina, Varna, Bulgaria.
Armstrong J; AstraZeneca, Cambridge, UK.
Byrne N; AstraZeneca, Cambridge, UK.
Thiyagarajah P; AstraZeneca, Cambridge, UK.
Jiang H; AstraZeneca, Gaithersburg, MD, USA.
Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: .
Pokaż więcej
Corporate Authors :
CASPIAN investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 51-65. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*administration & dosage
Cisplatin/*administration & dosage
Etoposide/*administration & dosage
Lung Neoplasms/*drug therapy
Small Cell Lung Carcinoma/*drug therapy
Aged ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Disease Progression ; Etoposide/adverse effects ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Progression-Free Survival ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Autorzy :
Wang Y; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Wang S; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Xu Y; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Wang P; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Li S; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Liu L; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Liu M; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Jin X; School of Pharmacy, Jilin University, Changchun, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 Oct 08; Vol. 15, pp. 7601-7613. Date of Electronic Publication: 2020 Oct 08 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Drug Compounding*
Etoposide/*administration & dosage
Etoposide/*pharmacology
Nanoparticles/*chemistry
Administration, Oral ; Analysis of Variance ; Animals ; Biological Availability ; Calorimetry, Differential Scanning ; Crystallization ; Etoposide/chemistry ; Etoposide/pharmacokinetics ; Freeze Drying ; Male ; Models, Statistical ; Particle Size ; Permeability ; Powders ; Rats, Sprague-Dawley ; Solubility ; Solvents ; Suspensions ; X-Ray Diffraction
Czasopismo naukowe
Tytuł :
Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
Autorzy :
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho Sunto-gun, Japan.
Niho S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tsuboi M; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Wakabayashi M; Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Ishii G; Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan.
Nakagawa K; Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Daga H; Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Saito H; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Aokage K; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho Sunto-gun, Japan.
Menju T; Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University.
Kasai T; Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
Yoshino I; Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Minato K; Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan.
Okada M; Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Eba J; Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Asamura H; Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Watanabe SI; Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 20; Vol. 38 (36), pp. 4292-4301. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Neuroendocrine/*drug therapy
Cisplatin/*therapeutic use
Etoposide/*therapeutic use
Irinotecan/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cisplatin/pharmacology ; Etoposide/pharmacology ; Female ; Humans ; Irinotecan/pharmacology ; Male ; Middle Aged ; Neoplasm Grading
Czasopismo naukowe
Tytuł :
Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Autorzy :
Fan Z; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Luo H; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Zhou J; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Wang F; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Zhang W; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Wang J; East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China.
Li S; Jake Gittlen Laboratories for Cancer Research, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Lai Q; Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, Fujian 361003, P.R. China.
Xu Y; Department of Pathology, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Wang G; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Liang A; Department of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, P.R. China.
Xu J; East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2020 Nov; Vol. 44 (5), pp. 2152-2164. Date of Electronic Publication: 2020 Sep 07.
Typ publikacji :
Journal Article
MeSH Terms :
DNA Damage*
DNA Repair*
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Checkpoint Kinase 1/*antagonists & inhibitors
Etoposide/*pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
4-Aminopyridine/administration & dosage ; 4-Aminopyridine/analogs & derivatives ; 4-Aminopyridine/pharmacology ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Checkpoint Kinase 1/metabolism ; Comet Assay/methods ; Drug Synergism ; Etoposide/administration & dosage ; Homologous Recombination ; Humans ; K562 Cells ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Pyrazines/administration & dosage ; Pyrazines/pharmacology ; Topoisomerase II Inhibitors/administration & dosage ; Topoisomerase II Inhibitors/pharmacology
Czasopismo naukowe
Tytuł :
Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties.
Autorzy :
Martin B; Université de Paris, CNRS, Inserm, UTCBS, Chemical and Biological Technologies for Health Group (utcbs.cnrs.fr), Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.; Department of Neurological Surgery, Weill Medical College of Cornell University, New York, NY, USA.
Seguin J; Université de Paris, CNRS, Inserm, UTCBS, Chemical and Biological Technologies for Health Group (utcbs.cnrs.fr), Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.
Annereau M; Gustave Roussy, 114 rue Edouard Vaillant, 94800, PharmacyVillejuif, France.
Fleury T; Gustave Roussy, 114 rue Edouard Vaillant, 94800, PharmacyVillejuif, France.
Lai-Kuen R; Université de Paris, CNRS, Inserm, Cellular and Molecular Imaging Technology Platform, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.
Neri G; Université de Paris, CNRS, Inserm, UTCBS, Chemical and Biological Technologies for Health Group (utcbs.cnrs.fr), Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.
Lam A; Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC, V6T 1Z1, Canada.
Bally M; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, V5Z 1L3, Canada.
Mignet N; Université de Paris, CNRS, Inserm, UTCBS, Chemical and Biological Technologies for Health Group (utcbs.cnrs.fr), Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France.
Corvis Y; Université de Paris, CNRS, Inserm, UTCBS, Chemical and Biological Technologies for Health Group (utcbs.cnrs.fr), Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006, Paris, France. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Oct 22; Vol. 10 (1), pp. 18059. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Nanoparticles*
Nanotechnology*
Antineoplastic Agents/*pharmacokinetics
Antineoplastic Agents/*pharmacology
Drug Compounding/*methods
Etoposide/*pharmacokinetics
Etoposide/*pharmacology
Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biological Availability ; Cell Line, Tumor ; Disease Models, Animal ; Dosage Forms ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Mice ; Suspensions
Czasopismo naukowe
Tytuł :
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Autorzy :
Ocadlikova D; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Iannarone C; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.
Redavid AR; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.
Cavo M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Curti A; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 16; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Etoposide/*pharmacology
Immunogenic Cell Death/*drug effects
Leukemia, Myeloid, Acute/*drug therapy
Vidarabine/*analogs & derivatives
Adenosine Triphosphate/metabolism ; Alarmins/metabolism ; Antineoplastic Agents/administration & dosage ; Calreticulin/metabolism ; Cell Line, Tumor ; Cytarabine/administration & dosage ; Cytarabine/pharmacology ; Daunorubicin/administration & dosage ; Daunorubicin/pharmacology ; Dendritic Cells/immunology ; Etoposide/administration & dosage ; Extracellular Space ; Gene Expression Regulation, Neoplastic/drug effects ; Heat-Shock Proteins/metabolism ; Humans ; Leukemia, Myeloid, Acute/immunology ; Lymphocyte Activation ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Organelles/metabolism ; Protein Transport/drug effects ; T-Lymphocyte Subsets/immunology ; Vidarabine/administration & dosage ; Vidarabine/pharmacokinetics
Czasopismo naukowe
Tytuł :
Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis.
Autorzy :
Saito S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Aiba H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. .
Yamada S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Okamoto H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hayashi K; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Kimura H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Miwa S; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Orthopedic Surgery, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Otsuka T; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Department of Education, Tokai Gakuen University, 2-901, Nakadaira, Tenpaku-ku, Nagoya, Aichi, 468-0014, Japan.
Murakami H; Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Sep 09; Vol. 20 (1), pp. 868. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
MeSH Terms :
Doxorubicin/*analogs & derivatives
Etoposide/*administration & dosage
Ifosfamide/*administration & dosage
Sarcoma/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Etoposide/adverse effects ; Female ; Humans ; Ifosfamide/adverse effects ; Leukopenia/chemically induced ; Leukopenia/pathology ; Male ; Middle Aged ; Sarcoma/pathology ; Thrombocytopenia/chemically induced ; Thrombocytopenia/pathology
Czasopismo naukowe
Tytuł :
R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.
Autorzy :
Bašić-Kinda S; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Radman I; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Dujmović D; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Ilić I; Department of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia.
Kralik M; Department of Radiology, University Hospital Centre Zagreb, Zagreb, Croatia.
Dobrenić M; Medical School, University of Zagreb, Zagreb, Croatia.; Department of Nuclear Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
Galunić-Bilić L; Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia.
Rončević P; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Vodanović M; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Sertić Z; Medical School, University of Zagreb, Zagreb, Croatia.
Hude I; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Aurer I; Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia. .; Medical School, University of Zagreb, Zagreb, Croatia. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jun; Vol. 100 (6), pp. 1517-1524. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Rituximab/*therapeutic use
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Rituximab/adverse effects ; Steroids/adverse effects ; Steroids/therapeutic use ; Treatment Outcome ; Vincristine/adverse effects ; Vincristine/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Autorzy :
Gao F; Deparment of Oncology, First Affiliated Hospital, Jilin University, Changchun, Jilin, PR China.
Cong X
Liu Z
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Oct 02; Vol. 99 (40), pp. e22637.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Etoposide/*therapeutic use
Small Cell Lung Carcinoma/*drug therapy
Small Cell Lung Carcinoma/*radiotherapy
Topoisomerase II Inhibitors/*therapeutic use
Administration, Oral ; Combined Modality Therapy ; Cranial Irradiation/methods ; Etoposide/administration & dosage ; Humans ; Indoles/therapeutic use ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Quinolines/therapeutic use ; Renal Dialysis/methods ; Renal Insufficiency/therapy ; Topoisomerase II Inhibitors/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Autorzy :
Baize N; Service de Cancérologie, Centre Hospitalier Universitaire d'Angers, Angers, France.
Monnet I; Service de Pneumologie, CHI Créteil, Créteil, France.
Greillier L; Aix-Marseille University, Marseille, France; Department of Multidisciplinary Oncology and Therapeutic Innovations, APHM, Hôpital Nord, Marseille, France; Department of Multidisciplinary Oncology and Therapeutic Innovations, Hôpital Nord, Marseille, France.
Geier M; Service de Pneumologie, CHU Brest, Brest, France.
Lena H; Service de Pneumologie, CHU Rennes, Rennes, France.
Janicot H; Service de Pneumologie, CHU Clermont-Ferrand, Clermont Ferrand, France.
Vergnenegre A; Service de Pneumologie, CHU Limoges, Limoges, France.
Crequit J; Service de Pneumologie, Centre Hospitalier de Beauvais, Beauvais, France.
Lamy R; Service de Pneumologie, CH Bretagne Sud, Lorient, France.
Auliac JB; Service de Pneumologie, CHI Créteil, Créteil, France.
Letreut J; Service de Pneumologie, Hôpital Européen, Marseille, France.
Le Caer H; Service de Pneumologie, Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France.
Gervais R; Service d'Oncologie, Centre François Baclesse, Caen, France.
Dansin E; Service d'Oncologie, Centre Oscar Lambret, Lille, France.
Madroszyk A; Service d'Oncologie, Institut Paoli-Calmettes, Marseille, France.
Renault PA; Service de Pneumologie, Centre Hospitalier de Pau, Pau, France.
Le Garff G; Service de Pneumologie, Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France.
Falchero L; Service de Pneumologie, Centre Hospitalier de Villefranche de Rouergue, Villefranche, France.
Berard H; Service de Pneumologie, Hôpital d'instruction des armées Sainte-Anne, Toulon, France.
Schott R; Service d'Oncologie, Centre Paul Strauss, Strasbourg, France.
Saulnier P; Département de Biostatistiques et Méthodologie, Centre Hospitalier Universitaire d'Angers, Angers, France.
Chouaid C; Service de Pneumologie, CHI Créteil, Créteil, France; Institut Mondor de Recherche Biomédicale, U955 Inserm-Université Paris Est Créteil, Créteil, France. Electronic address: .
Pokaż więcej
Corporate Authors :
Groupe Français de Pneumo-Cancérologie 01–13 investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Sep; Vol. 21 (9), pp. 1224-1233.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carboplatin/*administration & dosage
Etoposide/*administration & dosage
Small Cell Lung Carcinoma/*drug therapy
Topotecan/*administration & dosage
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Etoposide/adverse effects ; Female ; France/epidemiology ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Small Cell Lung Carcinoma/epidemiology ; Small Cell Lung Carcinoma/pathology ; Topotecan/adverse effects
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies